S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
Tesla inks deal to get key battery component outside China
In California pot market, a hazy line between legal and not
South Korean president visits UAE, showcasing deep ties
Rising costs add to pandemic pain for small businesses
The 5 Easiest To-Use Calendar Apps for Modern Day Working Adults
China's economy grows 8.1% in 2021, slows in second half
Group: Tax rich to fund vaccines for poor hit by pandemic
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
Tesla inks deal to get key battery component outside China
In California pot market, a hazy line between legal and not
South Korean president visits UAE, showcasing deep ties
Rising costs add to pandemic pain for small businesses
The 5 Easiest To-Use Calendar Apps for Modern Day Working Adults
China's economy grows 8.1% in 2021, slows in second half
Group: Tax rich to fund vaccines for poor hit by pandemic
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
Tesla inks deal to get key battery component outside China
In California pot market, a hazy line between legal and not
South Korean president visits UAE, showcasing deep ties
Rising costs add to pandemic pain for small businesses
The 5 Easiest To-Use Calendar Apps for Modern Day Working Adults
China's economy grows 8.1% in 2021, slows in second half
Group: Tax rich to fund vaccines for poor hit by pandemic
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
Tesla inks deal to get key battery component outside China
In California pot market, a hazy line between legal and not
South Korean president visits UAE, showcasing deep ties
Rising costs add to pandemic pain for small businesses
The 5 Easiest To-Use Calendar Apps for Modern Day Working Adults
China's economy grows 8.1% in 2021, slows in second half
Group: Tax rich to fund vaccines for poor hit by pandemic
NASDAQ:WVE

Wave Life Sciences Stock Forecast, Price & News

$2.63
+0.04 (+1.54%)
(As of 01/14/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.48
▼
$2.65
50-Day Range
$2.59
▼
$4.74
52-Week Range
$2.48
▼
$12.17
Volume
107,800 shs
Average Volume
245,540 shs
Market Capitalization
$154.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.49
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive WVE News and Ratings via Email

Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter.


Wave Life Sciences logo

About Wave Life Sciences

Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Headlines

What You Need To Know About Wave Life Sciences Ltd.'s (NASDAQ:WVE) Investor Composition
January 4, 2022 |  finance.yahoo.com
Vintage Wine Estates marks eight years and one million meals donated through its Angels Share campaign to fight food insecurity
December 31, 2021 |  finance.yahoo.com
Head to Head Comparison: Longboard Pharmaceuticals (NASDAQ:LBPH) versus Wave Life Sciences (NASDAQ:WVE)
December 27, 2021 |  americanbankingnews.com
How Good Are WAVE Life Sciences's Earnings? | Return On Capital Employed
November 11, 2021 |  benzinga.com
Wave Life Sciences (WVE) Reports Q3 Loss, Tops Revenue Estimates
November 10, 2021 |  finance.yahoo.com
WAVE Life Sciences earnings: here's what to expect
November 10, 2021 |  markets.businessinsider.com
Wave Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business Update
November 10, 2021 |  finance.yahoo.com
Wave Life Sciences to Present at the Stifel 2021 Virtual Healthcare Conference
November 8, 2021 |  finance.yahoo.com
Will Wave Life Sciences (WVE) Report Negative Q3 Earnings? What You Should Know
November 1, 2021 |  finance.yahoo.com
Wave Life Sciences to Webcast Conference Call of Third Quarter 2021 Financial Results on November 10, 2021
November 1, 2021 |  finance.yahoo.com
Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?
October 20, 2021 |  nasdaq.com
Wave Life Sciences and Takeda Amend CNS Collaboration
October 18, 2021 |  finance.yahoo.com
Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?
October 6, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:WVE
Previous Symbol
CUSIP
N/A
CIK
1631574
Web
www.wavelifesciences.com
Phone
(656) 236-3388
Fax
617-949-2901
Employees
219
Year Founded
N/A

Sales & Book Value

Annual Sales
$20.08 million
Price / Sales
7.71
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.70 per share
Price / Book
1.55

Profitability

EPS (Most Recent Fiscal Year)
($2.35)
Net Income
$-149.91 million
Net Margins
N/A
Pretax Margin
-240.74%
Return on Equity
-248.21%
Return on Assets
-50.06%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.99
Quick Ratio
4.99

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
58,833,000
Free Float
42,124,000
Market Cap
$154.73 million
Optionable
Optionable

Company Calendar

Last Earnings
11/10/2021
Today
1/17/2022
Next Earnings (Estimated)
3/03/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

2.22 out of 5 stars

Medical Sector

353rd out of 1,405 stocks

Pharmaceutical Preparations Industry

163rd out of 678 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Wave Life Sciences (NASDAQ:WVE) Frequently Asked Questions

Is Wave Life Sciences a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Wave Life Sciences stock.
View analyst ratings for Wave Life Sciences or view top-rated stocks.

How has Wave Life Sciences' stock been impacted by COVID-19?

Wave Life Sciences' stock was trading at $8.12 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, WVE shares have decreased by 67.6% and is now trading at $2.63.
View which stocks have been most impacted by COVID-19.

When is Wave Life Sciences' next earnings date?

Wave Life Sciences is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Wave Life Sciences.

How were Wave Life Sciences' earnings last quarter?

Wave Life Sciences Ltd. (NASDAQ:WVE) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.52. The firm had revenue of $36.42 million for the quarter, compared to analyst estimates of $10.70 million. During the same quarter last year, the business posted ($0.86) EPS.
View Wave Life Sciences' earnings history.

What price target have analysts set for WVE?

4 brokerages have issued 12-month target prices for Wave Life Sciences' stock. Their forecasts range from $7.00 to $17.00. On average, they expect Wave Life Sciences' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 280.2% from the stock's current price.
View analysts' price targets for Wave Life Sciences or view top-rated stocks among Wall Street analysts.

Who are Wave Life Sciences' key executives?

Wave Life Sciences' management team includes the following people:
  • Paul B. Bolno, President, Chief Executive Officer & Director
  • Kyle Moran, Chief Financial & Accounting Officer
  • Chandra Vargeese, Chief Technology Officer
  • Michael Panzara, Chief Medical Officer
  • Christopher Francis, SVP-Corporate Development & Head-Emerging Areas

What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO?

17 employees have rated Wave Life Sciences CEO Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among Wave Life Sciences' employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Wave Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN).

What is Wave Life Sciences' stock symbol?

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

How do I buy shares of Wave Life Sciences?

Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Wave Life Sciences' stock price today?

One share of WVE stock can currently be purchased for approximately $2.63.

How much money does Wave Life Sciences make?

Wave Life Sciences has a market capitalization of $154.73 million and generates $20.08 million in revenue each year. The company earns $-149.91 million in net income (profit) each year or ($2.35) on an earnings per share basis.

How many employees does Wave Life Sciences have?

Wave Life Sciences employs 219 workers across the globe.

What is Wave Life Sciences' official website?

The official website for Wave Life Sciences is www.wavelifesciences.com.

Where are Wave Life Sciences' headquarters?

Wave Life Sciences is headquartered at 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936.

How can I contact Wave Life Sciences?

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at (656) 236-3388, via email at [email protected], or via fax at 617-949-2901.


This page was last updated on 1/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.